LGD-4033 and SLU-PP-332 Interaction

Avoid
Mechanism-based 53% confidence

LGD-4033 and SLU-PP-332 have a potentially harmful interaction with 53% confidence. Both LGD-4033 and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

SLU-PP-332

Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator

Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.

Half-life: Under investigation (no human PK data) Typical dose: NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP) metabolic, longevity
ampk hepatotoxicinsulin disrupting
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Pancreas
low

Shared Safety Flags

2x 2 hepatotoxic compounds (LGD-4033, SLU-PP-332). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.

Frequently Asked Questions

Can I take LGD-4033 with SLU-PP-332?

Combining LGD-4033 with SLU-PP-332 is not recommended. Both LGD-4033 and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is LGD-4033 and SLU-PP-332 safe together?

This combination carries significant risk. Both LGD-4033 and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between LGD-4033 and SLU-PP-332?

Both LGD-4033 and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 53% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and SLU-PP-332?

LGD-4033 has a half-life of ~24-36 hours and SLU-PP-332 has a half-life of Under investigation (no human PK data). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: LGD-4033 vs SLU-PP-332

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.